Little Green Pharma (ASX:LGP) receives manufacturing permit


11 May 2020

Approved stamp image
Little Green Pharma has been granted a new manufacturing permit from the office of drug control

Medicinal cannabis company, Little Green Pharma (LGP) has been granted a new manufacturing permit from the office of drug control.

The manufacturing permit will allow the company to manufacture cannabis extracts for holders of therapeutic goods administration (TGA) GMP manufacturing licences to produce medicinal cannabis products.

Little Green has an exclusive agreement with its GMP-licenced manufacturing partner to produce the products.

The permit is valid for one year and ends in March 2021. This new permit will also allow the company to commence in-house extraction once the next crop is harvested, which is set to reduce costs and improve efficiencies.

Managing Director Fleta Solomon said receiving this permit also gives the company the capability to manufacture cannabis extracts at its manufacturing premises.

"We are now only waiting for our expanded ODC Medicinal Cannabis Cultivation and Production Permit which, once granted, will allow us to begin first planting at our expanded cultivation facility and to significantly expand our production operations," she said.

Read the full article by Lisa Simcock, Markets Reporter here:

You might also be interested in

Fleta Solomon LGP


Little Green Pharma to commence trading on ASX 20 February

Little Green Pharma raised the maximum subscription amount of $10 million in an oversubscribed IPO.

Feb 2020

First australian medical cannabis

Company news

First Australian-grown cannabis medicines

Little Green Pharma (LGP), is the first Australian company to locally-grow and produce medicinal cannabis products for sale to Australian patients. The first products are now ready to be delivered to patients.

Aug 2018


Company news

Export licence approved

The company has been granted an Export Licence by the Federal Department of Health

Jan 2019

View all articles